Acalabrutinib Phase III Study ELEVATE-TN achieves Primary Endpoint in Interim Analysis of Patients with untreated chronic lymphocytic Leukemia

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：420 / 420
页数：1
相关论文
共 50 条
  • [1] Elevate-TN: Impact of First-Year Dose Modifications in Patients with Treatment-Naive Chronic Lymphocytic Leukemia Treated with Acalabrutinib
    Follows, George
    Ferrajoli, Alessandra
    Byrd, John C.
    Shaw, Bob
    Nozaki, Kenji
    Stewart, Katherine
    De Miranda, Paulo Andre P. Palhares
    Sharman, Jeff P.
    BLOOD, 2023, 142
  • [2] Elevate Tn Phase 3 Study of Acalabrutinib Plus Obinutuzumab or Acalabrutinib Monotherapy vs Chlorambucil Plus Obinutuzumab (ClbO) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Martens, Uwe
    Sharman, Jeff
    Banerji, Versha
    Fogliatto, Laura Maria
    Herishanus, Yair
    Munir, Talha
    Walewska, Renato
    Follows, George
    Karlsson, Karin
    Ghia, Paolo
    Corbett, Gillian
    Walker, Patricia
    Egyed, Miklos
    Jurczak, Wojciech
    Salles, Gilles
    Janssens, Ann
    Cymbalista, Florence
    Wierda, William
    Coutre, Steven E.
    Pagel, John M.
    Skarbnik, Alan P.
    Kamdar, Manali
    Izumi, Raquel
    Munugala, Veerendra
    Patel, Priti
    Wang, Min Hui
    Wong, Sofia
    Woyach, Jennifer
    Byrd, John
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 127 - 127
  • [3] Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-TN study
    Sharman, Jeff P.
    Hakre, Shweta
    FUTURE ONCOLOGY, 2025, 21 (07) : 737 - 748
  • [4] Acalabrutinib ± Obinutuzumab versus Obinutuzumab plus Chlorambucil in Patients with therapy-naive chronic lymphocytic Leukemia: ELEVATE-TN 5-Year Follow-up
    Martens, U. M.
    Sharman, J. P.
    Egyed, M.
    Jurczak, W.
    Skarbnik, A.
    Kamdar, M.
    Munir, T.
    Fogliatto, L. M.
    Herishanu, Y.
    Banerji, V
    Follows, G.
    Walker, P.
    Karlsson, K.
    Ghia, P.
    Janssens, A.
    Ferrant, E.
    Munugalavadla, V
    Yu, T.
    Wang, M. H.
    Woyach, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 16 - 17
  • [5] PATIENT-REPORTED OUTCOMES FROM THE PHASE 3, RANDOMIZED STUDY OF ACALABRUTINIB WITH OR WITHOUT OBINUTUZUMAB VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB FOR TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA (ELEVATE-TN)
    Walker, P.
    Sharman, J. P.
    Jurczak, W.
    Munir, T.
    Banerji, V
    Coutre, S.
    Woyach, J.
    Salles, G.
    Wierda, W. G.
    Patel, P.
    Wang, M. H.
    Emeribe, U.
    Flood, E.
    Byrd, J. C.
    Ghia, P.
    VALUE IN HEALTH, 2021, 24 : S3 - S4
  • [6] Acalabrutinib ± Obinutuzumab Vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
    Sharman, Jeff P.
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Patel, Krish
    Flinn, Ian W.
    Kamdar, Manali
    Munir, Talha
    Walewska, Renata
    Hughes, Marie
    Fogliatto, Laura Maria
    Herishanu, Yair
    Banerji, Versha
    Follows, George
    Walker, Patricia A.
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Cymbalista, Florence
    Byrd, John C.
    Ferrant, Emmanuelle
    Ferrajoli, Alessandra
    Wierda, William G.
    Munugalavadla, Veerendra
    Wachira, Catherine Wangui
    Wun, Chuan-Chuan
    Woyach, Jennifer A.
    BLOOD, 2023, 142
  • [7] Acalabrutinib ± obinutuzumab vs obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up
    Martens, U. M.
    Sharman, J. P.
    Egyed, M.
    Jurczak, W.
    Skarbnik, A.
    Pagel, J. M.
    Kamdar, M.
    Munir, T.
    Corbett, G.
    Fogliatto, L. M.
    Herishanu, Y.
    Banerji, V
    Coutre, S.
    Walker, P.
    Karlsson, K.
    Ghia, P.
    Janssens, A.
    Wierda, W. G.
    Patel, P.
    Wang, M. H.
    Byrd, J. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 106 - 106
  • [8] ACALABRUTINIB ± OBINUTUZUMAB VERSUS OBINUTUZUMAB plus CHLORAMBUCIL IN CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT PREVIOUS TREATMENT: 4-YEAR FOLLOW-UP ELEVATE-TN
    Segundo Lucrecia, Yanez San
    Sharman, Jeff P.
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Pagel, John M.
    Kamdar, Manali
    Munir, Talha
    Corbett, Gillian
    Maria Fogliatto, Laura
    Herishanu, Yair
    Banerji, Versha
    Coutre, Steven
    Walker, Patricia
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Wierda, William G.
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    HAEMATOLOGICA, 2021, 106 (10) : 97 - 98
  • [9] Acalabrutinib ± Obinutuzumab vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up
    Sharman, Jeff P.
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Pagel, John M.
    Flinn, Ian W.
    Kamdar, Manali
    Munir, Talha
    Walewska, Renata
    Corbett, Gillian
    Fogliatto, Laura Maria
    Herishanu, Yair
    Banerji, Versha
    Coutre, Steven
    Follows, George
    Walker, Patricia
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Cymbalista, Florence
    Woyach, Jennifer A.
    Ferrant, Emmanuelle
    Wierda, William G.
    Munugalavadla, Veerendra
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S318 - S319
  • [10] Acalabrutinib ± obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: Elevate-TN four-year follow up.
    Sharman, Jeff Porter
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Pagel, John M.
    Kamdar, Manali K.
    Munir, Talha
    Corbett, Gillian
    Fogliatto, Laura Maria
    Herishanu, Yair
    Banerji, Versha
    Coutre, Steve E.
    Walker, Patricia
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Wierda, William G.
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345